Etana Biotechnologies to Produce mRNA-based COVID-19 Vaccines

By Editorial Team 29/07/2022
COVID-19 vaccine vials
Summary

Indonesia will produce messenger ribonucleic acid (mRNA)-based COVID-19 vaccine. PT Etana Biotechnologies Indonesia developed the new vaccine with a Chinese company, Suzhou Abogen Biosciences Co. Etana and Abogen will collaborate with the Faculty of Medicine, University of Indonesia (FKUI) Persahabatan Hospital (RSUP) for research, development, and clinical trials.

"With this collaboration, we expect more experts from Indonesia can master mRNA technology so that it can become a milestone in the development of biological products with mRNA platform," Etana Biotechnologies management said on Wednesday. The transfer of vaccine technology has started since the Etana team was in China. The local production facility has also received a Good Manufacturing Practice (GMP) certificate from the Food and Drug Monitoring Agency (BPOM).

Register now and get free access.

If you want to get free access to our Daily Insights and Weekly Digest, please click "Sign up" button below. If you already have an account, please login.

Sign up
Log in
What do subscribers receive?

As a subscriber, you'll receive daily insights, weekly business digests, and quarterly industrial reports.

What kind of pieces will i get?

In-depth reports on assumption and impact analysis, as well as update and trends mapping, written by our credible and experienced analysts.

And, there is something else…

Register now and get free access, click here to register. Feel free to contact us with any additional questions you have.